argenx SE research snapshot
ARGX AI stock analysis currently reads argenx SE as a profitable, commercial-stage immunology company whose VYVGART franchise is growing quickly across autoimmune indications. At the July 11, 2026 data cutoff, the latest StockAnalysis close was $909.59 on July 8 and the reported market capitalization was about $56.71 billion. The opportunity depends on durable VYVGART demand, label expansion, and pipeline execution, while concentration, clinical, pricing, and valuation risks remain material. This is informational research, not investment advice.
Current price
$909.59
Market cap
About $56.7 billion
AI score
72 / 100
Rating
Profitable immunology leader with VYVGART concentration and pipeline risk
Trend status
Constructive trend near resistance, with catalyst-driven volatility
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | argenx earns product revenue from VYVGART and its subcutaneous forms, medicines that reduce pathogenic IgG antibodies in serious autoimmune diseases. | High |
| Moat | The moat combines first-mover FcRn clinical evidence, regulatory approvals, prescriber relationships, global launch infrastructure, manufacturing know-how, and expanding administration options. | Medium-high |
| Management | Karen Massey became CEO in May 2026 after serving as COO, creating an execution transition to monitor while the company scales VYVGART and a broader immunology pipeline. | Medium |
| Financial trend | FY2025 revenue was about $4.25 billion and profit was $1.29 billion. Q1 2026 VYVGART product sales reached $1.3 billion, up about 63% year over year. | High |
| Valuation | At $909.59, the verified TTM PE was about 37.9x and price to book was about 7.7x. The valuation assumes continuing growth, high margins, and successful development. | Medium-high |
| Technical trend | The latest ChartMill snapshot showed positive short and long trends, a support band near $839 to $878, and resistance near $940. Price action remains event-sensitive. | Medium |
| Risk level | Risk is high because VYVGART is the dominant franchise and biotechnology outcomes depend on reimbursement, competitive therapies, labels, clinical data, and intellectual property. | High |
| AI confidence | Reported facts and valuation math are well supported. Exact price outcomes are not reliably predictable, especially around clinical and regulatory catalysts. | High data confidence |
| Investment certainty | Medium certainty. The franchise and balance sheet are strong, but the stock leaves less room for slower growth, competition, or pipeline disappointment. | Medium |
ARGX AI stock forecast
The ARGX AI stock forecast uses scenario math around the $909.59 quote and estimated TTM EPS of $23.99. The auditable three-year framework produced values near $2,372 in the bullish case, $1,451 in the base case, and $798 in the bearish case. These are scenario outputs, not price targets or promises.
$2,250 to $2,500
More likely if VYVGART continues rapid global patient growth, new indications expand the addressable market, myositis data and other pipeline programs succeed, and investors continue to pay a premium multiple for durable immunology growth.
$1,350 to $1,550
More likely if product growth remains strong but normalizes, operating investment stays elevated, label expansion progresses, and the market applies a mid-30s earnings multiple to compounded EPS.
$750 to $850
More likely if new-patient growth slows, competitors or payer restrictions pressure VYVGART economics, clinical data disappoints, or the market rerates the company toward a lower earnings multiple.
ARGX AI technical analysis
ARGX AI technical analysis is constructive as of the July 11, 2026 cutoff, but it should be treated as a dated chart snapshot. ChartMill reported a positive short and long trend on July 6, with a broad support band at $838.72 to $877.71 and resistance at $939.69. The latest StockAnalysis close was $909.59 on July 8.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $909.59 | StockAnalysis closing snapshot from July 8, 2026, used for market-cap and valuation math. |
| Near support | $839 to $878 | ChartMill support zone created by multiple trend lines and moving averages across time frames. |
| Secondary support | $782 | ChartMill identified a horizontal daily support reference near $782.17. |
| Moving averages | Positive trend snapshot | ChartMill described both short and long trends as positive. Recheck live moving averages before acting. |
| Resistance | About $940 | ChartMill identified a resistance area near $939.69, close to the recent trading range high. |
| Momentum | Constructive, near resistance | The setup was consolidating near the top of a wide monthly range, so confirmation requires price and volume. |
| Volume | Monitor catalyst volume | Compare volume with earnings, label decisions, trial data, and competitive FcRn news rather than using price alone. |
| Volatility | High | Biotechnology valuation can move sharply on clinical, regulatory, reimbursement, and pipeline information. |
| Invalidation | Close below $839, then $782 | A decisive break below the support band weakens the swing setup and calls for a fresh review of fundamentals and price action. |
ARGX AI trading strategy
The ARGX AI trading strategy is a general framework for a catalyst-sensitive biotechnology stock. It is not personalized advice and should be used with live prices, position sizing, earnings dates, trial calendars, and independent research.
Watch whether ARGX holds the $839 to $878 support area and breaks above roughly $940 with volume confirmation while VYVGART sales and pipeline news remain intact.
Define risk before entry. A close below $839 weakens the setup, while a break below $782 should trigger a full review rather than averaging down automatically.
If ARGX falls toward support without a negative clinical, regulatory, payer, or competitor event, compare the price move with Q1 sales growth, cash, valuation, and upcoming catalysts.
Do not assume every drop is an opportunity. Product concentration and new medical data can permanently alter the earnings path.
Track VYVGART patient growth, indication and geography mix, net price and reimbursement, gross margin, R&D spending, cash and current financial assets, shares, FcRn competitors, and clinical readouts.
Lower conviction if franchise growth slows before the pipeline broadens, if price concessions rise, or if valuation depends mainly on a multiple rather than delivered earnings.
Investment research summary
argenx converts FcRn biology, clinical development, regulatory approvals, and specialist commercial execution into VYVGART sales for patients with serious autoimmune disease.
The moat rests on first approved FcRn leadership, evidence in approved diseases, prescriber familiarity, patient services, global commercialization, formulation options, and a pipeline that can build on the same immunology capability. It narrows if competitors match outcomes, convenience, access, or price.
The thesis fails if VYVGART growth decelerates, payer controls or competition reduce economics, new indications do not convert, clinical programs fail, intellectual property protection weakens, or the earnings multiple contracts.
The management question is whether the new CEO can maintain commercial discipline while allocating substantial cash flow to trials, future FcRn molecules, manufacturing, geographic expansion, and the next wave of immunology assets.
Autoimmune medicine is a long-duration growth market because many diseases remain underdiagnosed and undertreated. Value creation depends on clinical differentiation, safety, access, and the ability to reach patients, not just on a large theoretical patient population.
ARGX trades at a premium valuation because earnings are growing quickly and the market values future indications. Margin of safety improves if VYVGART growth and pipeline evidence exceed expectations, and shrinks if the growth curve or multiple normalizes.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ARGX price and market capitalization | $909.59 close on July 8, 2026 and $56.71 billion reported market capitalization | StockAnalysis statistics snapshot | July 11, 2026 |
| Market capitalization verification | $56.45 billion calculated as $909.59 x 62.06 million shares, a 0.46% difference from reported market capitalization | financial_rigor.py using StockAnalysis price and shares | July 11, 2026 |
| FY2025 revenue | About $4.25 billion, up about 88.6% year over year | argenx Annual Report 2025, Macrotrends, and StockAnalysis cross-check | July 11, 2026 |
| FY2025 profit | $1.292 billion | argenx Annual Report 2025 and Macrotrends cross-check | July 11, 2026 |
| Q1 2026 VYVGART product net sales | $1.3 billion, compared with $0.8 billion in Q1 2025 | argenx Q1 2026 financial results | July 11, 2026 |
| Q1 2026 profit and diluted EPS | $366 million and $5.52 | argenx Q1 2026 financial results | July 11, 2026 |
| Cash and current financial assets | $4.9 billion at March 31, 2026. StockAnalysis showed $4.44 billion cash and a $4.39 billion net-cash figure on a different snapshot, so these values are not treated as the same reporting-period measure. | argenx Q1 2026 financial results and StockAnalysis | July 11, 2026 |
| Technical support and resistance | Support $838.72 to $877.71 and resistance near $939.69 | ChartMill technical analysis | July 11, 2026 |
This ARGX AI stock analysis page is an informational research tool only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of July 11, 2026 and can be wrong if financial results, clinical data, regulatory decisions, reimbursement, competition, interest rates, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
